Search Back New search Go to resultsDiseaseMain groupHematological Diseases, Non-MalignantProtocol groupAnemias, CytopeniasDiseaseAnemia, Autoimmune Hemolytic AnemiaImmune ThrombocytopeniaSubgroupalso in pregnancyICD10D59.1D69.3MeSHAnemia, Hemolytic, AutoimmunePurpuraPurpura, Thrombocytopenic, IdiopathicSequenceChemotherapyChemo-substanceDaratumumabDexamethasoneRituximabVincristineChemo-substanceDaratumumabDexamethasoneRituximabVincristineChemo-substanceDaratumumabDexamethasoneRituximabVincristineChemo-substanceDaratumumabDexamethasoneRituximabVincristineNo. Substances12 RadiotherapySupportive therapySupportive substanceAciclovirAvatrombopagBalanced Crystalloid SolutionDexamethasoneDimetindenEltrombopagFostamatinibHuman immunoglobulin (IVIg)MontelukastParacetamolPrednisoloneRomiplostimSupportive substanceAciclovirAvatrombopagBalanced Crystalloid SolutionDexamethasoneDimetindenEltrombopagFostamatinibHuman immunoglobulin (IVIg)MontelukastParacetamolPrednisoloneRomiplostimSupportive substanceAciclovirAvatrombopagBalanced Crystalloid SolutionDexamethasoneDimetindenEltrombopagFostamatinibHuman immunoglobulin (IVIg)MontelukastParacetamolPrednisoloneRomiplostimSupportive substanceAciclovirAvatrombopagBalanced Crystalloid SolutionDexamethasoneDimetindenEltrombopagFostamatinibHuman immunoglobulin (IVIg)MontelukastParacetamolPrednisoloneRomiplostimNo. Substances145Protocol classificationTherapy classificationalternativecurrent standardIntensityStandard doseTherapy indicationFirst lineRefractory diseaseRelapse therapySecond lineseveral possibleThird line Therapy phaseTherapy intentiondisease controlsupportiveRisksAlopeciaAnemia Hb below 8g/dlArthalgiaAstheniaBleedingCardiotoxicityDiarrheaEmetogenicity (MASCC/ESMO)Gastrointestinal ToxicityHeadacheHemorrhageHepatotoxicityHypertensionIncrease AminotransferasesInfectionsInfusion ReactionNauseaNeuropathyNeutropeniaPainPyrexiaRashThrombocytopenia below 50 000/µlThromboembolic EventUpper Respiratory Tract InfectionVomiting only studiesPublicationAuthorAndersen JBussel JCrickx EGodeau BJurczak WKuter DPark YDiseaseautoimmune ThrombozytopenieChronische Immunthrombozytopenie, therapierefraktärChronische Immunthrombozytopenie, vortherapiertChronische ITP, therapierefraktär, Karnofsky über 70ITP, splenektomiert und nicht-splenektomiert, Thrombozytenzahlen < 30 000/µlITP, splenektomiert und nicht-splenektomiert, Thrombozytenzahlen im Durchschnitt 30 000/µlITP, Zweitlinie, Thrombozytenzahlen < 30000/µl, Kandidaten für eine SplenektomieKortikoid-refraktäre ITP, splenektomiertsymptomatische Thrombozytopenie, teilweise trotz PrednisolonOriginAssistance Publique Hopitaux de Paris, Universite Paris Est Creteil, 94000 CreteilDepartment of Haematology, Jagiellonian University, Krakow, PolandDepartment of Hematology‑Oncology, Inha University College of Medicine and Hospital, Shinheung‑dong Jung‑gu, Incheon, Republic of KoreaDivision of Hematology and Oncology, Department of Internal Medicine, Wayne State University School of Medicine and Harper Hospital, DetroitGroupe d'Étude du Traitement du PTAIMassachusetts General Hospital, Boston, MA, USAMédecine Interne, Hôpital Henri-Mondor, Assistance Publique–Hôpitaux de ParisWeill-Cornell Medical College of Cornell University, New York, NY, USAWeill Cornell Medicine, New York, USAProtocols in Revision 9 protocols foundProtocols under revision.Avatrombopag 20, Immune Thrombocytopenia (PID1800 V1.0)Daratumumab 16 / Dexamethasone 20, Immune Thrombocytopenia (PID2863 V1.0)Dexamethasone 40, Immune Thrombocytopenia (PID956 V1.0)Eltrombopag 50, Immune Thrombocytopenia (PID954 V1.0)Fostamatinib 100, Immune Thrombocytopenia (PID1063 V1.0)Intravenous Immunoglobulin-G 1, Immune Thrombocytopenia (PID955 V1.0)Rituximab 375, Immune Thrombocytopenia (PID957 V1.0)Romiplostim 1, Immune Thrombocytopenia (PID953 V1.0)Vincristine 1.5, Immune Thrombocytopenia (PID958 V1.0)
